XBIT - Multiplikator Forward P/S XBiotech
XBiotech Inc. (XBIT) relies on a narrow development portfolio, making its resilience dependent on trial outcomes. Success is based on the confirmed efficacy of "human" antibodies and patent protection. A unique synthesis without side effects will allow the company to maintain pricing power. The expected P/S trend illustrates market expectations, with the metric settling at 597.60.
XBIT (xbiotech.com): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- statistik kapitalisasi pasar:
- statistik nilai buku emiten:
- data liabilitas lan likuiditas perusahaan:
Total Utang marang Modal XBiotech Inc.|XBIT - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang modal XBiotech|XBIT - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku XBIT|XBIT - Silihan lan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan XBiotech|Rasio cepet xbiotech.com
- data bathi bisnis lan rasio investasi:
XBIT - Asil keuangan resik|Bathi sing dikarepake XBiotech Inc.|XBIT - Pangali rega marang bathi|Pangali Forward P/E XBiotech|XBIT - Pangali rega marang bathi tumrap wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan XBIT|XBIT - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan XBiotech|XBIT - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan xbiotech.com|XBIT - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep XBiotech Inc.
- rincian pendapatan lan dodolan:
Analisis kabeh metrik perusahaan:XBiotech USA XBIT
XBiotech Inc. (XBIT) investments in a unique antibody platform and the retention of R&D specialists establish a foundation for future revenues, which are valued through the ratio of current market capitalization to projected revenue per share. An analysis of the expected price-to-sales ratio allows for the determination of asset overbought conditions, signaling to institutional investors the need to review capital concentration risks when the indicator reaches extreme values.
Pesaing wigati
Multiplikator Forward P/S ONC (BeiGene)|Halozyme Therapeutics, Inc. - Rasio rega marang prakiraan pendapatan|RevMed - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Ascentage Pharma Corp AAPG|CG Oncology, Inc. (CGON) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep urogen.com (URGN)|Multiplikator forward rega marang pendapatan BCAX|PSNL (Personalis Inc) - Rasio rega marang pendapatan sing dikarepake|Multiplikator Forward P/S ERAS|DCTH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S YMAB (Y-mAbs Therapeutics)|AURA - Multiplikator forward rega marang pendapatan|Candel - Multiplikator Forward P/S|Rega forward marang dodolan ARAY (Accuray Inc)|SLS (sellaslifesciences.com) - Multiplikator forward rega marang pendapatan|Actuate Therapeutics Inc - Rega forward marang dodolan|CTOR (Citius Oncology, Inc.) - Multiplikator Forward P/S|TuHURA (HURA) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Protara Therapeutics, Inc. (TARA)|Fate Therapeutics Inc - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S WHWK (Aadi Bioscience)|TCRX - Multiplikator forward rega marang pendapatan|CSBR: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake CEL-SCI Corporation CVM|OSTX (OS Therapies) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan RADX|ARTV (Artiva Biotherapeutics Inc.) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan ANL|Multiplikator Forward P/S VERU|Rasio kapitalisasi marang dodolan sing dikarepake tempesttx.com|Xilio Therapeutics - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake RENB (Renovaro Biosciences)|Mural Bio - Multiplikator Forward P/S|Kairos Pharma Ltd (KAPA) - Multiplikator forward rega marang pendapatan|OKUR: Multiplikator Forward P/S|CytoMed Therapeutics Limited (GDTC) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan Curis Inc.|Kapitalisasi marang prakiraan pendapatan APLM (Apollomics Corp)|Multiplikator Forward P/S THAR|Multiplikator forward rega marang pendapatan advanbiomed.com ADVB|Multiplikator Forward P/S GNPX (Genprex, Inc.)|Calidi Biotherapeutics Inc. (CLDI) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|SBFM - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan XBIO (Xenetic Biosciences)|SLRX (Salarius) - Multiplikator forward rega marang pendapatan|Kitov Pharma - Rega forward marang dodolan|AONC (American Oncology Network Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan beigene.com (BGNE)|Multiplikator forward rega marang pendapatan CKPT (Checkpoint Therapeutics, Inc.)|Multiplikator Forward P/S elevationoncology.com (ELEV)|Rasio rega marang prakiraan pendapatan iCAD ICAD|Rega forward marang dodolan IKNA|Notable Labs, Ltd. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Viracta Therapeutics|MOR (MorphoSys) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan NAYA|AAPGV (Ascentage Pharma Group Ltd) - Multiplikator Forward P/S
